In pre-clinical studies, radiotherapy combined with PD-1 [15–17], PD-L1 [18–20], and CTLA-4 [21, 22] inhibitors improved long-term survival and prevented tumor recurrence under a variety of fractionated doses. Here, PDCD1 is linked to neoplasm.